Add-on Acquisition • Life Science

Genexine Acquires Argos Therapeutics

On February 13, 2019, Genexine acquired life science company Argos Therapeutics for 11M USD

Acquisition Context

This is Genexine’s 1st transaction in the Life Science sector.
This is Genexine’s largest (disclosed) transaction.
This is Genexine’s 1st transaction in the United States.
This is Genexine’s 1st transaction in North Carolina.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	February 13, 2019
Target	Argos Therapeutics
Sector	Life Science
Buyer(s)	Genexine
Deal Type	Add-on Acquisition
Deal Value	11M USD

Target Company

Argos Therapeutics

Durham, North Carolina, United States

Argos Therapeutics, Inc. is a developer of therapeutic vaccines against carcinoma, melanoma, leukemia and HIV. Argos Therapeutics, Inc. was formed in 1997 and is headquartered in Durham, North Carolina.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Genexine

Seoul, South Korea

Category	Company
Founded	1999
Sector	Life Science
Employees	86
Revenue	2.9B KRW (2024)

DESCRIPTION

Genexine is a clinical-stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next-generation novel long-acting biologics. Genexine was founded in 1999 and is based in Seoul, South Korea.

Deal Context for Buyer	#
Overall	1 of 1
Sector: Life Science	1 of 1
Type: Add-on Acquisition	1 of 1
State: North Carolina	1 of 1
Country: United States	1 of 1
Year: 2019	1 of 1
Size (of disclosed)	1 of 1

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - North Carolina M&A - United States M&A - 2019 M&A